Clinical Trial

Different First-line Immunotherapy for Advancer Hepatocellular Carcinoma: A Prospective Observational Study on Efficacy and Immune Microenvironment

Study acronym: HCC-IM-1
Recruiting
View on ClinicalTrials.gov →
Summary
To evaluate the efficacy and immune microenvironment changes in advanced hepatocellular carcinoma (HCC) patients receiving different first-line immunotherapy.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-08-21.
Status change: Not Yet Recruiting → Recruiting 2026-04-18
Trial Details
NCT Number NCT07147101
Lead Sponsor Fudan University
Conditions Advanced Hepatocellular Carcinoma (HCC)
Enrollment 150 participants
Start Date 2025-09-01
Primary Completion 2028-09-01 (estimated)
Study Completion 2028-09-01 (estimated)
Updated on ClinicalTrials.gov 2026-04-21